Hemosense, a manufacturer of handheld blood coagulation monitors for users of the drug warfarin, announced Wednesday afternoon a further reduction in its price range per share to $6 to $8. The originally filed range was $8 to $10. The company plans on selling 3.5 million shares on the offering. Lazard will act as the lead manager on the deal. Expect the stock to begin trading this week on the AMEX under the symbol "HEM."
